Compare Incyte Corporation (INCY) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares Ultra Gold ETF — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while ProShares Ultra Gold ETF trades at $44.93. The key difference: Incyte Corporation is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| INCY | UGL | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $85.62 |
52-Week Low | $67.38 | $33.59 |
Enterprise Value | $19.13B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
